tbuckley/cabot-search huggingface dataset:
AIE‐Active Glycomimetics Triggered Bacterial Agglutination and Membrane‐Intercalating toward Efficient Photodynamic Antiseptic
Authors: Qiaoni Guo, Shaobo Xue, Jianguo Feng, Chen Peng, Chengcheng Zhou, Yan Qiao
Journal: Advanced Healthcare Materials (2023)

Opportunistic infections caused by Pseudomonas aeruginosa (P. aeruginosa) are particularly difficult to treat due to the altered membrane permeability and inherent resistance to conventional antibiotics. Here, a cationic glycomimetics is designed and synthesized with aggregation-induced emission (AIE) characteristics namely TPyGal, which self-assembles into the spherical aggregates with galactosylated surface. TPyGal aggregates can effectively cluster P. aeruginosa through multivalent carbohydrate-lectin interactions and auxiliary electrostatic interactions and subsequently trigger membrane-intercalating, which results in efficient photodynamic eradication of P. aeruginosa under white light irradiation by in situ singlet oxygen (1 O2 ) burst to disrupt bacterial membrane. Furthermore, the results demonstrate that TPyGal aggregates promote the healing of infected wounds, indicating the potential for clinical treatment of P. aeruginosa infections.
Safety, tolerability and efficacy of up‐titration of guideline‐directed medical therapies for acute heart failure in elderly patients: A sub‐analysis of the <scp>STRONG‐HF</scp> randomized clinical trial
Authors: Mattia Arrigo, Jan Biegus, Ayu Asakage, Alexandre Mebazaa, Beth Davison, Christopher Edwards, Marianna Adamo, Marianela Barros, Jelena Celutkiene, Kamilė Čerlinskaitė‐Bajorė, Ovidiu Chioncel, Albertino Damasceno, Rafael Diaz, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S.P. Lam, Marco Metra, Maria Novosadova, Matteo Pagnesi, Peter S. Pang, Piotr Ponikowski, Hadiza Saidu, Karen Sliwa, Koji Takagi, Jozine M. Ter Maaten, Daniela Tomasoni, Adriaan A. Voors, Gad Cotter, Alain Cohen‐Solal
Journal: European Journal of Heart Failure (2023)

STRONG-HF examined a high-intensity care (HIC) strategy of rapid up-titration of guideline-directed medical therapy (GDMT) and close follow-up after acute heart failure (AHF) admission. We assess the role of age on efficacy and safety of HIC.Hospitalized AHF patients, not treated with optimal GDMT were randomized to HIC or usual care. The primary endpoint of 180-day death or HF readmission occurred equally in older (>65 years, n = 493, 74 ± 5 years) and younger patients (53 ± 11 years, adjusted hazard ratio [aHR] 1.02, 95% confidence interval [CI] 0.73-1.43, p = 0.89). Older patients received slightly lower GDMT to day 21, but same doses at day 90 and 180. The effect of HIC on the primary endpoint was numerically higher in younger (aHR 0.51, 95% CI 0.32-0.82) than older patients (aHR 0.73, 95% CI 0.46-1.15, adjusted interaction p = 0.30), partially related to COVID-19 deaths. After exclusion of COVID-19 deaths, the effect of HIC was similar in younger (aHR 0.51, 95% CI 0.32-0.82) and older patients (aHR 0.63, 95% CI 0.32-1.02, adjusted interaction p = 0.56), with no treatment-by-age interaction (interaction p = 0.57). HIC induced larger improvements in quality of life to day 90 in younger (EQ-VAS adjusted-mean difference 5.51, 95% CI 3.20-7.82) than in older patients (1.77, 95% CI -0.75 to 4.29, interaction p = 0.032). HIC was associated with similar rates of adverse events in older and younger patients.High-intensity care after AHF was safe and resulted in a significant reduction of all-cause death or HF readmission at 180 days across the study age spectrum. Older patients have smaller benefits in terms of quality of life.
Effect of anatomical liver resection for hepatocellular carcinoma: a systematic review and meta-analysis
Authors: Seong Wook Shin, Tae-Seok Kim, Keun Soo Ahn, Yong Hoon Kim, Koo Jeong Kang
Journal: International Journal of Surgery (2023)

Despite retrospective studies comparing anatomical liver resection (AR) and non-anatomical liver resection (NAR), the efficacy and benefits of AR for hepatocellular carcinoma remain unclear.The authors systemically reviewed MEDLINE, Embase, and Cochrane Library for propensity score matched cohort studies that compared AR and NAR for hepatocellular carcinoma. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS). Secondary outcomes were recurrence patterns and perioperative outcomes.Overall, 22 propensity score matched studies (AR, n =2,496; NAR, n =2590) were included. AR including systemic segmentectomy was superior to NAR regarding the 3-year and 5-year OS. AR showed significantly better 1-year, 3-year, and 5-year RFS than NAR, with low local and multiple intrahepatic recurrence rates. In the subgroup analyses of tumour diameter less than or equal to 5 cm and tumours with microscopic spread, the RFS in the AR group was significantly better than that in the NAR group. Patients with cirrhotic liver in the AR group showed comparable 3-year and 5-year RFS with the NAR group. Postoperative overall complications were comparable between AR and NAR.This meta-analysis demonstrated that AR showed better OS and RFS with a low local and multiple intra-hepatic recurrence rate than NAR, especially in patients with tumour diameter less than or equal to 5 cm and non-cirrhotic liver.
<i>Ex vivo</i> to <i>in vivo</i> model of malignant peripheral nerve sheath tumors for precision oncology
Authors: Alex T Larsson, Himanshi Bhatia, Ana Calizo, Kai Pollard, Xiaochun Zhang, Eric Conniff, Justin F Tibbitts, Elizabeth Rono, Katherine Cummins, Sara H Osum, Kyle B Williams, Alexandra L Crampton, Tyler Jubenville, Daniel Schefer, Kuangying Yang, Yang Lyu, James C Pino, Jessica Bade, John M Gross, Alla Lisok, Carina A Dehner, John S A Chrisinger, Kevin He, Sara J C Gosline, Christine A Pratilas, David A Largaespada, David K Wood, Angela C Hirbe
Journal: Neuro-Oncology (2023)

Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1). To address the critical need for novel therapeutics in MPNST, we aimed to establish an ex vivo 3D platform that accurately captured the genomic diversity of MPNST and could be utilized in a medium-throughput manner for drug screening studies to be validated in vivo using patient-derived xenografts (PDX). Methods Genomic analysis was performed on all PDX-tumor pairs. Selected PDX were harvested for assembly into 3D microtissues. Based on prior work in our labs, we evaluated drugs (trabectedin, olaparib, and mirdametinib) ex vivo and in vivo. For 3D microtissue studies, cell viability was the endpoint as assessed by Zeiss Axio Observer. For PDX drug studies, tumor volume was measured twice weekly. Bulk RNA sequencing was performed to identify pathways enriched in cells. Results We developed 13 NF1-associated MPNST-PDX and identified mutations or structural abnormalities in NF1 (100%), SUZ12 (85%), EED (15%), TP53 (15%), CDKN2A (85%), and chromosome 8 gain (77%). We successfully assembled PDX into 3D microtissues, categorized as robust (&amp;gt;90% viability at 48 h), good (&amp;gt;50%), or unusable (&amp;lt;50%). We evaluated drug response to “robust” or “good” microtissues, namely MN-2, JH-2-002, JH-2-079-c, and WU-225. Drug response ex vivo predicted drug response in vivo, and enhanced drug effects were observed in select models. Conclusions These data support the successful establishment of a novel 3D platform for drug discovery and MPNST biology exploration in a system representative of the human condition.
Rural-urban differences in characteristics, postoperative outcomes, and costs for patients undergoing knee arthroplasty: a national retrospective propensity score matched cohort study
Authors: Huizhong Long, Dongxing Xie, Hu Chen, Jie Wei, Xiaoxiao Li, Haibo Wang, Chao Zeng, Guanghua Lei
Journal: International Journal of Surgery (2023)

The rural-urban disparities in postoperative complications and costs among patients undergoing knee arthroplasty (KA) have not been thoroughly explored. This study aimed to determine whether such differences exist in this patient population.The study was conducted using data from the national Hospital Quality Monitoring System of China. Hospitalized patients undergoing KA from 2013 to 2019 were enrolled. Patient and hospital characteristics were compared between rural and urban patients, and differences in postoperative complications, readmissions, and hospitalization costs were analyzed using propensity score matching.Of the 146 877 KA cases analyzed, 71.4% (104 920) were urban patients and 28.6% (41 957) were rural patients. Rural patients tended to be younger (64.4±7.7 years vs. 68.0±8.0 years; P <0.001) and had fewer comorbidities. In the matched cohort of 36 482 participants per group, rural patients were found to be more likely to experience deep vein thrombosis (OR: 1.31, 95% CI: 1.17-1.46; P <0.001) and require red blood cell (RBC) transfusion (OR: 1.38, 95% CI: 1.31-1.46; P <0.001). However, they had a lower incidence of readmission within 30 days (OR: 0.65, 95% CI: 0.59-0.72; P <0.001) and readmission within 90 days (OR: 0.61, 95% CI: 0.57-0.66; P <0.001) than their urban counterparts. In addition, rural patients incurred lower hospitalization costs than urban patients (57 396.2 Chinese Yuan vs. 60 844.3 Chinese Yuan; P <0.001).Rural KA patients had different clinical characteristics compared with urban patients. While they had a higher likelihood of deep vein thrombosis and RBC transfusion following KA than urban patients, they had fewer readmissions and lower hospitalization costs. Targeted clinical management strategies are needed for rural patients.
Prevalence of obstructive sleep apnea–hypopnea in severe versus moderate asthma
Authors: Joanne Y. Julien, James G. Martin, Pierre Ernst, Ronald Olivenstein, Qutayba Hamid, Catherine Lemière, Carmela Pepe, Naftaly Naor, Allen Olha, R. John Kimoff
Journal: Journal of Allergy and Clinical Immunology (2009)
Asymmetrical Obstacles Enable Unilateral Inertial Focusing and Separation in Sinusoidal Microchannel
Authors: Haotian Cha, Yuchen Dai, Helena H. W. B. Hansen, Lingxi Ouyang, Xiangxun Chen, Xiaoyue Kang, Hongjie An, Hang Thu Ta, Nam-Trung Nguyen, Jun Zhang
Journal: Cyborg and Bionic Systems (2023)

Inertial microfluidics uses the intrinsic fluid inertia in confined channels to manipulate the particles and cells in a simple, high-throughput, and precise manner. Inertial focusing in a straight channel results in several equilibrium positions within the cross sections. Introducing channel curvature and adjusting the cross-sectional aspect ratio and shape can modify inertial focusing positions and can reduce the number of equilibrium positions. In this work, we introduce an innovative way to adjust the inertial focusing and reduce equilibrium positions by embedding asymmetrical obstacle microstructures. We demonstrated that asymmetrical concave obstacles could break the symmetry of original inertial focusing positions, resulting in unilateral focusing. In addition, we characterized the influence of obstacle size and 3 asymmetrical obstacle patterns on unilateral inertial focusing. Finally, we applied differential unilateral focusing on the separation of 10- and 15-μm particles and isolation of brain cancer cells (U87MG) from white blood cells (WBCs), respectively. The results indicated an excellent cancer cell recovery of 96.4% and WBC rejection ratio of 98.81%. After single processing, the purity of the cancer cells was dramatically enhanced from 1.01% to 90.13%, with an 89.24-fold enrichment. We believe that embedding asymmetric concave micro-obstacles is a new strategy to achieve unilateral inertial focusing and separation in curved channels.
Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements
Authors: Michelle W.J. Heijman, Aernoud T.L. Fiolet, Arend Mosterd, Jan G.P. Tijssen, Bart J.F. van den Bemt, Astrid Schut, John W. Eikelboom, Peter L. Thompson, Cornelia H.M. van den Ende, Stefan M. Nidorf, Calin D. Popa, Jan H. Cornel
Journal: Annals of Internal Medicine (2023)

Background: Osteoarthritis is a major contributor to pain and disability worldwide. Given that inflammation plays an important role in the development of osteoarthritis, anti-inflammatory drugs may slow disease progression. Objective: To examine whether colchicine, 0.5 mg daily, reduces incident total knee replacements (TKRs) and total hip replacements (THRs). Design: Exploratory analysis of the LoDoCo2 (Low-Dose Colchicine 2) randomized, controlled, double-blind trial. (Australian New Zealand Clinical Trials Registry: ACTRN12614000093684) Setting: 43 centers in Australia and the Netherlands. Patients: 5522 patients with chronic coronary artery disease. Intervention: Colchicine, 0.5 mg, or placebo once daily. Measurements: The primary outcome was time to first TKR or THR since randomization. All analyses were performed on an intention-to-treat basis. Results: A total of 2762 patients received colchicine and 2760 received placebo during a median follow-up of 28.6 months. During the trial, TKR or THR was performed in 68 patients (2.5%) in the colchicine group and 97 (3.5%) in the placebo group (incidence rate, 0.90 vs. 1.30 per 100 person-years; incidence rate difference, −0.40 [95% CI, −0.74 to −0.06] per 100 person-years; hazard ratio, 0.69 [CI, 0.51 to 0.95]). In sensitivity analyses, similar results were obtained when patients with gout at baseline were excluded and when joint replacements that occurred in the first 3 and 6 months of follow-up were omitted. Limitation: LoDoCo2 was not designed to investigate the effect of colchicine in osteoarthritis of the knee or hip and did not collect information specifically on osteoarthritis. Conclusion: In this exploratory analysis of the LoDoCo2 trial, use of colchicine, 0.5 mg daily, was associated with a lower incidence of TKR and THR. Further investigation of colchicine therapy to slow disease progression in osteoarthritis is warranted. Primary Funding Source: None.
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
Authors: Yanshuo Chu, Enyu Dai, Yating Li, Guangchun Han, Guangsheng Pei, Davis R. Ingram, Krupa Thakkar, Jiang-Jiang Qin, Minghao Dang, Xiuning Le, Can Hu, Qing Deng, Ansam Sinjab, Pravesh Gupta, Ruiping Wang, Dapeng Hao, Fuduan Peng, Xinmiao Yan, Yunhe Liu, Shumei Song, Shaojun Zhang, John V. Heymach, Alexandre Reuben, Yasir Y. Elamin, Melissa P. Pizzi, Yang Lu, Rossana Lazcano, Jian Hu, Mingyao Li, Michael Curran, Andrew Futreal, Anirban Maitra, Amir A. Jazaeri, Jaffer A. Ajani, Charles Swanton, Xiang-Dong Cheng, Hussein A. Abbas, Maura Gillison, Krishna Bhat, Alexander J. Lazar, Michael Green, Kevin Litchfield, Humam Kadara, Cassian Yee, Linghua Wang
Journal: Nature Medicine (2023)
Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases
Authors: Pravat Kumar Parida, Mauricio Marquez-Palencia, Suvranil Ghosh, Nitin Khandelwal, Kangsan Kim, Vidhya Nair, Xiao-Zheng Liu, Hieu S. Vu, Lauren G. Zacharias, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Bret C. Mobley, Jeffrey G. McDonald, Andrew Lemoff, Yan Peng, Cheryl Lewis, Gonçalo Vale, Nils Halberg, Carlos L. Arteaga, Ariella B. Hanker, Ralph J. DeBerardinis, Srinivas Malladi
Journal: Nature Cancer (2023)
Polygenic prediction of preeclampsia and gestational hypertension
Authors: Michael C. Honigberg, Buu Truong, Raiyan R. Khan, Brenda Xiao, Laxmi Bhatta, Ha My T. Vy, Rafael F. Guerrero, Art Schuermans, Margaret Sunitha Selvaraj, Aniruddh P. Patel, Satoshi Koyama, So Mi Jemma Cho, Shamsudheen Karuthedath Vellarikkal, Mark Trinder, Sarah M. Urbut, Kathryn J. Gray, Ben M. Brumpton, Snehal Patil, Sebastian Zöllner, Mariah C. Antopia, Richa Saxena, Girish N. Nadkarni, Ron Do, Qi Yan, Itsik Pe’er, Shefali Setia Verma, Rajat M. Gupta, David M. Haas, Hilary C. Martin, David A. van Heel, Triin Laisk, Pradeep Natarajan
Journal: Nature Medicine (2023)
Lessons learned from translating AI from development to deployment in healthcare
Authors: Kasumi Widner, Sunny Virmani, Jonathan Krause, Jay Nayar, Richa Tiwari, Elin Rønby Pedersen, Divleen Jeji, Naama Hammel, Yossi Matias, Greg S. Corrado, Yun Liu, Lily Peng, Dale R. Webster
Journal: Nature Medicine (2023)
Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection
Authors: Joshua J. Meeks, Peter C. Black, Matthew Galsky, Petros Grivas, Noah M. Hahn, Syed A. Hussain, Matthew I. Milowsky, Gary D. Steinberg, Robert S. Svatek, Jonathan E. Rosenberg
Journal: European Urology (2023)
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Authors: Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Journal: Journal of Hematology & Oncology (2023)

We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8 years, p < 0.0001, had better transplantation comorbidity index (HCT-CI) ≥ 3 21.3% versus 40.8%, p < 0.0001 and Karnofsky performance status (KPS) with KPS ≥ 90 in 78% versus 68.5%, respectively, p = 0.002. The two patient groups did not differ with respect to gender, cytomegalovirus serostatus, and cell source. Median time from diagnosis to HaploSCT was 5.2 versus 4.9 months, respectively, p = 0.005. Fewer sAML patients received myeloablative conditioning 35.1% versus 50.1%, p < 0.0001. Two hundred and eleven sAML and 410 de novo AML patients were included in the matched-pair analysis matching two de novo AML with each sAML. No significant difference was observed in any transplantation outcome parameter between the sAML versus de novo AML groups. Two-year non-relapse mortality and relapse incidence did not differ with HaploSCT for de novo versus sAML; 21.4% versus 21%, hazard ratio (HR) = 0.98, p = 0.9 and 23.4% versus 20.6%, HR = 0.92, p = 0.67, respectively. Two-year leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, relapse-free survival were also not different between the de novo AML and sAML groups 55.2% versus 58.4%, HR = 0.95, p = 0.67; 61.4% versus 66.4%, HR = 0.91, p = 0.51 and 46.3% versus 48.2%, HR = 0.92, p = 0.48, respectively. Similarly, the incidence of engraftment as well as acute and chronic GVHD was similar between the 2 cohorts. In conclusion, HaploSCT with PTCy may be able to overcome the bad prognosis of sAML as results are not significantly different to those of HaploSCT in de novo AML.
Mass cytometry uncovers a distinct peripheral immune profile and upregulated CD38 expression in patients with hidradenitis suppurativa
Authors: Peter Dimitrion, Iltefat Hamzavi, Congcong Yin, Jugmohit Toor, Kalpana Subedi, Namir Khalasawi, Angela Miller, Richard Huggins, Indra Adrianto, Jesse Veenstra, Gautham Vellaichamy, Aakash Hans, Steven Daveluy, Mohammad Athar, Wilson Liao, Henry Lim, David Ozog, Li Zhou, Qing-Sheng Mi
Journal: Cellular and Molecular Immunology (2023)
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
Authors: Mark D Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P Cope, James B Galloway
Journal: Annals of the Rheumatic Diseases (2023)

To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate.Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) compared with placebo, TNFi or methotrexate, in adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease or atopic dermatitis. Network and pairwise meta-analyses were performed to estimate incidence rate ratios (IRRs) for malignancy between JAKi and comparators. Bias was assessed using the Cochrane Risk of Bias-2 tool.In 62 eligible RCTs and 16 LTE studies, there were 82 366 person-years of exposure to JAKi, 2924 to placebo, 7909 to TNFi and 1074 to methotrexate. The overall malignancy incidence rate was 1.15 per 100 person-years in RCTs, and 1.26 per 100 person-years across combined RCT and LTE data. In network meta-analyses, the incidence of all malignancies including non-melanomatous skin cancers (NMSCs) was not significantly different between JAKi and placebo (IRR 0.71; 95% CI 0.44 to 1.15) or between JAKi and methotrexate (IRR 0.77; 95% CI 0.35 to 1.68). Compared with TNFi, however, JAKi were associated with an increased incidence of malignancy (IRR 1.50; 95% CI 1.16 to 1.94). Findings were consistent when analysing NMSC only and when analysing combined RCT/LTE data.JAKi were associated with a higher incidence of malignancy compared with TNFi but not placebo or methotrexate. Cancers were rare events in all comparisons.CRD42022362630.
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
Authors: Birgit Geoerger, Manuel Schiff, Virginie Penard-Lacronique, Niklas Darin, Selim-Maria Saad, Clarisse Duchon, Antonin Lamazière, Aurore Desmons, Clément Pontoizeau, Pablo Berlanga, Stéphane Ducassou, Katharine Yen, Michael Su, David Schenkein, Chris Ottolenghi, Stéphane De Botton
Journal: Nature Medicine (2023)
Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States
Authors: George Goshua, Cecelia Calhoun, Satoko Ito, Lyndon P. James, Andrea Luviano, Lakshmanan Krishnamurti, Ankur Pandya
Journal: Annals of Internal Medicine (2023)

Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities in SCD, but distributional CEA (DCEA) uses equity weights to incorporate these considerations.
The Efficacy of Nanoparticle Delivery to Hypoxic Solid Tumors by ciRGD Co‐Administration Depends on Neuropilin‐1 and Neutrophil Levels
Authors: Mukaddes Izci, Christy Maksoudian, Filipa Gonçalves, Irati Pérez Gilabert, Carla Rios Luci, Eduardo Bolea‐Fernandez, Frank Vanhaecke, Bella B. Manshian, Stefaan J. Soenen
Journal: Advanced Healthcare Materials (2023)

Abstract The ability to improve nanoparticle delivery to solid tumors is an actively studied domain, where various mechanisms are looked into. In previous work, the authors have looked into nanoparticle size, tumor vessel normalization, and disintegration, and here it is aimed to continue this work by performing an in‐depth mechanistic study on the use of ciRGD peptide co‐administration. Using a multiparametric approach, it is observed that ciRGD can improve nanoparticle delivery to the tumor itself, but also to tumor cells specifically better than vessel normalization strategies. The effect depends on the level of tumor perfusion, hypoxia, neutrophil levels, and vessel permeability. This work shows that upon characterizing tumors for these parameters, conditions can be selected that can optimally benefit from ciRGD co‐administration as a means to improve NP delivery to solid tumors.
Mental Stress Testing in Women With Angina and No Obstructive Coronary Artery Disease
Authors: Huan Ma, Wei Jiang, Lan Guo, Han Yin, Haochen Wang, Yuting Liu, Bingqing Bai, Quanjun Liu, Shuxia Wang, Qingshan Geng
Journal: Journal of the American College of Cardiology (2023)